Quantcast

Latest MS Stories

2014-09-12 23:00:59

In what may be the largest study of sleep problems among individuals with multiple sclerosis (MS), researchers at UC Davis have found that widely undiagnosed sleep disorders may be at the root of the most common and disabling symptom of the disease: fatigue. Sacramento, CA (PRWEB) September 12, 2014 In what may be the largest study of sleep problems among individuals with multiple sclerosis (MS), researchers at UC Davis have found that widely undiagnosed sleep disorders may be at the root...

2014-09-12 08:25:30

International Progressive MS Alliance established as worldwide collaborative with goal to find solutions and treatments for progressive MS BOSTON, Sept. 12, 2014 /PRNewswire-USNewswire/ -- The International Progressive MS Alliance has awarded its first round of 22 research grants to investigators in 9 countries, with the goal of removing barriers to developing treatments for progressive MS. The Alliance is a worldwide collaborative focused on finding solutions to progressive forms of...

2014-09-12 08:25:21

- Research grants awarded for five out of more than 200 proposals, highlighting continued commitment to multiple sclerosis (MS) ROCKLAND, Mass., Sept. 12, 2014 /PRNewswire/ -- EMD Serono Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the recipients of the second annual Grant for Multiple Sclerosis Innovation (GMSI) at the 2014 Joint ACTRIMS-ECTRIMS Meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee for Treatment and...

2014-09-10 08:32:02

- EMD Serono provides funding for ACP's multicenter longitudinal OPT-UP clinical study ROCKLAND and WALTHAM, Mass., Sept. 10, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany and the Accelerated Cure Project for Multiple Sclerosis today announced a lead founding sponsor agreement to help launch the Optimizing Treatment--Understanding Progression (OPT-UP) study. http://photos.prnewswire.com/prnvar/20140902/141783...

2014-09-09 23:00:26

People with multiple sclerosis (MS) lose myelin in the gray matter of their brains and the loss is closely correlated with the severity of the disease, according to a new magnetic resonance imaging (MRI) study that appears online, September 10, in the journal Radiology. OAK BROOK, Ill. (PRWEB) September 09, 2014 People with multiple sclerosis (MS) lose myelin in the gray matter of their brains and the loss is closely correlated with the severity of the disease, according to a new magnetic...

2014-09-09 16:25:56

- Data include post-hoc assessments of controlled studies in relapsing MS regarding evolution of gadolinium-enhancing lesions, assessments of predictive scores for disease activity and disability progression, and 'no evident disease activity' (NEDA) measure for interferon beta-1a SC vs. interferon beta-1a IM ROCKLAND, Mass., Sept. 9, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the division's multiple sclerosis...

2014-09-09 04:21:06

~Convening World's Leading Researchers in MS with a Program Covering all Aspects of Research Including Cause and Pathology, Genetics and Environmental Impact, Emerging Treatment Study Findings and Nervous System Repair BOSTON, Sept. 9, 2014 /PRNewswire/ -- On September 10-13 at the Hynes Convention Center in Boston, MA, ACTRIMS-ECTRIMS will host their joint triennial international meeting - MSBoston 2014, with over 8,000 participant from leading organizations in Europe, North America and...

2014-09-08 08:29:26

--Phase 2a Trial is First to Use Crowdsourcing for Protocol Design and Telemonitoring for Patient Data Collection-- NEW YORK, Sept. 8, 2014 /PRNewswire/ -- Transparency Life Sciences, LLC (TLS), the world's first clinical-stage drug development company based on open innovation, today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive...

2014-09-04 12:26:34

DIEPENBEEK, Belgium, September 4, 2014 /PRNewswire/ -- Scientists discover how to 'switch off' autoimmune diseases Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that Bristol University research led by Apitope Founder and CSO, Prof David Wraith, on its treatment approach to autoimmune diseases, such as Multiple Sclerosis (MS), has been published...

2014-09-04 04:21:59

~Crew of Sailors with MS including Bostonian Demonstrate Ability to Overcome Personal Challenges BOSTON, Sept. 4, 2014 /PRNewswire/ -- On Thursday, September 11th at 8:30 a.m., MSBoston2014 -- the world's largest international conference exclusively devoted to research in multiple sclerosis (MS) -- will host its opening ceremony with Dr. Dhib-Jalbut, President of ACTRIMS, providing an overarching look at the MS landscape. In his address, he will underscore the critical importance of MS...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.